Company valuation ยท Healthcare
LMAT: Hold + Add with a $123.23 price target
LeMaitre Vascular Inc. Year-to-date profit has improved, but working capital is growing faster than sales.
- Model target ยท USD
- $123.23 For 2027-09-17
- Model rating
- Hold + Add Reviewed 2026-09-16
- Reference weekly close
- $80.59 2026-09-11 ยท USD

Investment view
Year-to-date profit has improved, but working capital is growing faster than sales.
Target and reference price
Target for 2027-09-17: $123.23 USD, +52.9% versus the $80.59 weekly close on 2026-09-11. Price return only; dividends, fees and tax excluded.
Price and earnings
Over 1 year (2025-09-12 to 2026-09-11), price changed -12.7% and trailing EPS changed +38.3%. A wider gap changes the earnings multiple; it does not establish fair value.
Supporting evidence
Across 2 completed quarters since 2025-12-31, net income was 32.7m versus 24.8m in the matching prior-year periods (USD). Check whether the latest quarter changes that direction.
The latest quarterly operating margin was 29.0%, +3.9 percentage points from a year earlier. The full report separates sales growth from margin changes.
Risks to the case
Inventory changed +22.7%, against sales of +9.6%, from the same quarter last year. This can tie up cash. Acquisitions, payment timing and seasonality also need checking.
The estimate for the period ending 2026-12-31 changed -4.0% over 30 days. Coverage is 8 analysts.
What to monitor
Compare the next results with the trailing margin of 29.5% and the annual-history median of 23.6%. A historical median is context, not a forecast.
The latest quarterly margin changed +3.9 percentage points from a year earlier. Check sales volumes, pricing and unusual gains in the next filing.
Recheck the valuation gap alongside profitability and growth after new results. A discount alone does not establish value.
Valuation assumptions
Starting annual sales growth: 11.26%.
Net profit margin: 21.22%.
About this assessment
Review recorded on 2026-09-16. This is a dated summary of an automated company valuation. The full report includes the financial evidence, alternative scenarios and review history. Consult the latest report before using an earlier target. Automated model research, not personal investment advice. Targets depend on assumptions; returns are not guaranteed.